18 maggio 2017
Replacement therapy and its complications in older adults
P. Andreozzi, G. Innico, M. Mangiulli, Y. Esposito, P. Protopapa,
A. Perrotta, V. D’Ambrosio, A. Currado, F. Aucella
Department of Clinical Medicine, Sapienza University of Rome, Rome
In questo lavoro viene descritto il caso clinico di una donna affetta da malattia di Alzheimer in cui la diagnosi precoce, seguita da un altrettanto precoce trattamento sia farmacologico che di riabilitazione neurocognitiva, hanno consentito una lunga sopravvivenzascarica PDF
”Chronic kidney disease in older adults”
”Sarcopenia, dynapenia, malnutrition and frailty”
inflammatory response (11). The prevalence of sarcopenia in clinical trials changes depending on the chosen definition, considering the loss of the 8% of the muscular mass every ten years until the age of 70, with a consecutive loss of the 13-24% every ten years (12-14) and the loss of the 50% of muscular mass in dialyzed patients, where it is often ignored or under diagnosed (15).
A lot of CKD-connected conditions are able to accelerate muscular loss such as metabolic acidosis, low protein diet, no physical activities, insulin resistance, osteoporosis and Vitamine D deficiency (12-13). An important role was also attributed to a low grade chronic inflammation, since it is an important pathogenetic factor of accelerated atherosclerosis in CKD (16).
Protein-energy wasting (PEW) is another frequent problem in older adults with CKD (18-75%), especially if they are treated with renal replacement therapy (17). PEW’s causes in CKD are various (Table 1) and they can lead to a syndrome called “Malnutrition-Inflammation Complex Syndrome” (MICS) or to “Malnutrition-Inflammation-Atherosclerosis” syndrome (MIA) with a worse quality of life and an increased morbidity and mortality (18-19).
Therefore it is recommended a routine assessment of the nutritional status to diagnose and manage the MICS through various methods, such as the Subjective
Global Assessment (SGA), the malnutrition inflammation score (MIS), composed of four sections (nutritional history, physical examination, BMI and laboratory tests), that correlates with nutritional status, inflammation and mortality in dialyzed patients (20), the Geriatric Nutritional Risk Index (GNRI), which considers albumin’s values and the relationship between current weight and ideal weight according to Lorentz’s formula and it is also able to predict the risk of complications and malnutrition-related mortality (20).
Another common condition in elderly patients is frailty, a biological syndrome characterized by a reduced reserve and resistance to stress factors. It is caused by a multiple physiological-systems failure and it can cause frailty to negative events. The expression «frail elderly» was used for the first time in 1974 by the Federal Council of Ageing and since then, a lot of definitions were attributed to it, but Fried et al. (21)
were the first to define a frail phenotype and to separate it from co-morbidities and disability.
Frailty, malnutrition, sarcopenia and dynapenia are associated with reduced physical performances, disability, a worse quality of life and reduced survival. They can be caused by ageing, CKD or both conditions, indeed, some aspects of CKD, as modified protein metabolism, inflammation, oxidative stress and anemia, are more likely to accelerate the ageing process, leading to frailty (22).
In these patients, the nutritional support (for example with food integrator) is essential (19), but in the last few years, physical activity has become more important. Constant and moderate physical activity should
be encouraged and frequently monitored in these patients, considering any possible orthopedic, cardiovascular or neurological limitations by giving self-report questionnaires [(Short Form-36 (SF36), Patient Reported Outcomes Measurement Information System (PROMIS), Katz, Independence in Daily Living questionnaire (ADL), Lawton, InstrumentalActivities of Daily Living (IADL)], by diagnostic procedures (cardio-pulmonary test, muscular assessment) and by giving «field test» to evaluate motility
and physical abilities (GaitSpeed, WalkingTests, Chair Standsetc) (23).
”Dialysis or conservative-palliative therapy”
The choice between starting dialysis or conservative therapy supported by a palliative treatment affects a large number of older adults, their families and health resources.
Recent evidence suggests that many patients over the age of 75, with more comorbidities, have a life expectancy and quality of life considerably low in dialysis (26-27).
Some studies have suggested an equal survival of older adults with multiple comorbidities, or poor physical functions, on conservative and on dialysis treatment, while other authors reported even a longer survival with palliative therapy (28- 30).
Moreover, older adults on replacement therapy, have different needs than younger patients, so could be indicated a personalized replacement therapy (31), as home dialysis or assisted peritoneal dialysis.
The selection of the most appropriate options should comply with the individual needs, considering various aspects such as the patient’s choice, his/her psychological and clinical status, the social and family context, with a nephrological, geriatric and psychological team, which aims not only to prolong life expectancy, but also to improve the quality of life.
The Planning Preventive Care (PCP) is a process of discussion between an individual and his doctor regarding the concerns, the goals, the preferences, the prognosis and future therapy (32-33).
Therefore, it’s essential to correctly inform the patient and his family about the prognosis, the life expectancy, the quality of life, the risks, the benefits and the responsibilities of the offered therapy.
Conservative-palliative therapy provide a careful patient care, managing anemia, metabolic acidosis, hypertension and controlling fluids balance, symptoms such as pain, mental health problems, as depression, always considering the spiritual needs of the patient; indeed, spirituality and faith play an important role in doctorpatient relationship, and for the quality of life, by ensuring a good “end of life”, often through collaboration between nephrologists and palliativists in structures called “hospice” (34-36).
The prognostic knowledge of the outcome in older adult patients can influence treatment decisions, but often it mainly depends on the personal nature of clinical judgment.
A prognostic tool, currently used, is based on the presence of five variables such as age, dementia, peripheral vascular disease, decreased albumin concentration and the answer ‘no’ to the question ‘would you be surprised if the patient died in the next six months?’ (37).
Indexes such as the Multidimensional Prognostic Index (MPI) (38), which is a prognostic index of mortality in the short (1 month) and long-term (one year) based on information obtained from a Multidimensional Evaluation (VMD) of older adult (Table 2), have been developed during the last few years: classifying the risk of death of elderly patients in slight-middlesevere.
The indexes considerably help the physician in such a difficult choice.
The clinical picture is characterized by an executive and motoric decline and mnemonic, linguistic and cognitive deficits; it is attributed to brain’s white matter diseases, to often clinically silent, cerebral infarctions (42), and typical hematochemical, acid–base homeostasis and hydroelectrolytic modifications (43).
Cognitive impairment can affect treatment adherence, by affecting the efficiency of daily activities, such as the proper intake of medications and diet, and it’s a significant prognosis factor for high morbidity and mortality in dialysis patients.
Moreover, CKD patients have a higher rate of psychological disorders, including depression associated with Vitamin D deficiency and with an inflammatory pathogenesis (44). These diseases greatly reduce the quality of life and have a negative impact on patient compliance, on clinical outcome and therefore on health care costs (45). Furthermore, in current clinical practice, we evaluate the survival but also the general health status and satisfaction towards the therapy, that allows a good patient compliance in
addition to a considerable decrease of national health costs. For this reason it may be important to evaluate cognitive abilities, the psychological state of health and quality of life of older adult patients with CKD by giving them diagnostic tests, such as the Mini-Mental State Examination (MMSE) (46), the Montreal Cognitive Assessment (MoCA) (47), the Geriatric Depression Scale (GDS) (48) and the Short Form 36 Health Survey (SF-36) (Table 3), with a multidisciplinary management by a team of geriatricians, neurologists, psychologists or psychiatrists.
”Kidney transplantation in elderly patients”
or living donors with a diagnosis of malignant tumor, people with potential and contagious infections or suffering from kidney cysts (51).
The Senior Program Eurotransplant (52) is an “old to old” system of allocation, highlighting the importance of keeping the time of ischemia short at a low temperature and of innovative techniques of conservation and allocation. The most common problems of non-optimal kidneys transplants are a delayed recover of organ functionality and the transplant failure in the short or long term, even if the first long term results show the same survival rate in both patient and transplanted organ as in non-marginal transplants.
This is true only if an appropriate and standardized pre-transplant bioptical (52-53) valuation is done, reducing the waiting lists. Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. The manuscript has been seen and approved by all authors. This study was not funded.
The manuscript is not under consideration for publication elsewhere
1. Hallan SI, Orth SR The conundrum of chronic kidney disease classification and end-stage renal risk prediction in the elderly—what is the right approach? Nephron. Clinical practice 2010;116(4):c307-16.
2. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA
2007 Nov 7;298(17):2038-47.
3. De Nicola L, Donfrancesco C, Minutolo R et al. [Epidemiology of chronic kidney disease in Italy: current
state and contribution of the CARHES study]. Giornale italiano di nefrologia: organo ufficiale della Societa
italiana di nefrologia 2011 Jul-Aug;28(4):401-7.
4. Schmidt RJ Informing our elders about dialysis: is an ageattuned approach warranted? Clinical journal of the American Society of Nephrology: CJASN 2012 Jan;7(1):185-91.
5. Shum CK, Tam KF, Chak WL et al. Outcomes in older adults with stage 5 chronic kidney disease: comparison of peritoneal dialysis and conservative management. The journals of gerontology. Series A, Biological sciences and medical sciences 2014 Mar;69(3):308-14.
6. Collins AJ, Kasiske B, Herzog C, Chen SC, Everson S, Constantini E, Grimm R, McBean M, Xue J, Chavers B, Matas A, Manning W, Louis T, Pan W, Liu J, Li S, Roberts T, Dalleska F, Snyder J, Ebben J, Frazier E, Sheets D, Johnson R, Li S, Dunning S, Berrini D, Guo H, Solid C, Arko C, Daniels F, Wang X, Forrest B, Gilbertson D, St Peter W, Frederick P, Eggers P, Agodoa L. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003 Dec;42(6 Suppl 5):A5-7, S1-230.
7. Udayaraj U1, Tomson CR, Gilg J, Ansell D, Fogarty D.UK Renal Registry 11th Annual Report (December 2008): Chapter 6 Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales and Northern Ireland: national and centre-specific analyses. Nephron Clin-Pract. 2009;111Suppl 1:c97-111.
8. Foley RN, Parfrey PS, SarnakMJ.Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9.
9. Alexandre Tda S, Duarte YA, Santos JL et al. Sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP) versus dynapenia as a risk factor for mortality in the elderly. The journal of nutrition, health & aging 2014;18(8):751-6.
10. Biolo G, Cederholm T, Muscaritoli M et al. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clinical nutrition (Edinburgh, Scotland) 2014 Oct;33(5):737-48. Zembroń-Łacny A, Dziubek W, Rogowski Ł et al. arcopenia: monitoring, molecular mechanisms, and physical intervention. Physiological research / Academia ScientiarumBohemoslovaca 2014;63(6):683-91 (full text).
12. Fahal IH Uraemic sarcopenia: aetiology and implications. Nephrology, dialysis, transplantation :
official publication of the European Dialysis and Transplant Association – European Renal Association
13. Patel SS, Molnar MZ, Tayek JA et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. Journal of cachexia, sarcopenia and muscle 2013 Mar;4(1):19-29 (full text).
14. Kalantar-Zadeh K, Cano NJ, Budde K et al. Diets and enteral supplements for improving outcomes in chronic kidney disease. Nature reviews. Nephrology 2011 May 31;7(7):369-84.
15. Cerri AP, Bellelli G, Mazzone A et al. Sarcopenia and malnutrition in acutely ill hospitalized elderly: Prevalence and outcomes. Clinical nutrition (Edinburgh, Scotland) 2015 Aug;34(4):745-51.
16. Cruz-Jentoft AJ, Landi F, Schneider SM et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age and ageing 2014 Nov;43(6):748-59.
17. Jadeja YP, Kher V Protein energy wasting in chronic kidney disease: An update with focus on nutritional interventions to improve outcomes. Indian journal of endocrinology and metabolism 2012
18. Kalantar-Zadeh K, Ikizler TA, Block G et al. Malnutritioninflammation complex syndrome in dialysis patients: causes and consequences. American journal of kidney diseases: the official journal of the National Kidney Foundation 2003 Nov;42(5):864-81.
19. Kovesdy CP, Kopple JD, Kalantar-Zadeh K et al. Management of protein-energy wasting in non-dialysisdependent chronic kidney disease: reconciling low protein intake with nutritional therapy. The American journal of clinical nutrition 2013 Jun;97(6):1163-77.
20. Riella MC Nutritional evaluation of patients receiving dialysis for the management of protein-energy
wasting: what is old and what is new? Journal of renal nutrition : the official journal of the Council on
Renal Nutrition of the National Kidney Foundation 2013 May;23(3):195-8.
21. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. The journals of gerontology. Series A, Biological sciences and medical sciences 2001 Mar;56(3):M146-56.
22. Kim JC, Kalantar-Zadeh K, Kopple JD et al. Frailty and proteinenergy wasting in elderly patients with end stage kidney disease. Journal of the American Society of Nephrology : JASN 2013 Feb;24(3):337-51.
23. Painter P, Marcus RL Assessing physical function and physical activity in patients with CKD. Clinical journal of the American Society of Nephrology : CJASN 2013 May;8(5):861-72.
24. Brunori G Treatment of chronic kidney disease in the elderly:diet or conservative management. Journal of nephrology 2012;25Suppl 19:S28-31.
25. Hussain JA, Mooney A, Russon L et al. Comparison of survivalanalysis and palliative care involvement in patients aged over 70 years choosing conservative management or renal replacement therapy in advanced chronic kidney disease. Palliative medicine 2013 Oct;27(9):829-39.
26. Fassett RG Current and emerging treatment options for the elderly patient with chronic kidney disease. Clinical interventions in aging 2014;9:191-9.
27. Beben T, Rifkin DE The Elderly are Different: Initiating Dialysis in Frail Geriatric Patients. Seminars in dialysis 2015 May- Jun;28(3):221-3.
28. Treit K, Lam D, O’Hare AM et al. Timing of dialysis initiation in the geriatric population: toward a patient-centered approach. Seminars in dialysis 2013 Nov-Dec;26(6):682-9.
29. Farragher J, Jassal SV Rehabilitation of the geriatric dialysis patient. Seminars in dialysis 2012 Nov-Dec;25(6):649-56.
30. Foote C, Kotwal S, Gallagher M et al. Survival outcomes of supportive care versus dialysis therapies for elderly patients with end-stage kidney disease: A systematic review and meta-analysis. Nephrology (Carlton, Vic.) 2016 Mar;21(3):241-53.
31. Power A, Brown E Optimising treatment of endstage renal disease in the elderly. Nephron. Clinicalpractice 2013;124(3-4):202-8.
32. Brunori G. Terapia nutrizionale nell’IRC in fase conservativa: suggerimenti di pratica clinica e di applicazione delle Linee Guida. G Ital Nefrol 2013; 30 (Suppl. 59): 1-11. 58.
33. Musso CG, Trigka K, Dousdampanis P et al. Therapeutic alternatives and palliative care for advanced renal disease in the very elderly: a review of the literature. International urology and nephrology 2015 Apr;47(4):647-54.
34. Walker SR, Wagner M, Tangri N et al. Chronic kidney disease, frailty, and unsuccessful aging: a review. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2014 Nov;24(6):364-70.
35. RodriguezVillarreal I, Ortega O, Hinostroza J et al. Geriatric assessment for therapeutic decision-making regarding renal replacement in elderly patients with advanced chronic kidney disease. Nephron. Clinicalpractice 2014;128(1-2):73-8.
36. Lucchetti G, Almeida LG, Granero AL et al. [Spirituality for dialysis patients: should the nephrologist address?]. Jornal brasileiro de nefrologia : ‘orgaooficial de Sociedades Brasileira e Latino-Americana de Nefrologia 2010 Mar;32(1):126-30.
37. Hall RK, O’Hare AM, Anderson RA et al. End-stage renal disease in nursing homes: a systematic review. Journal of the American Medical Directors Association 2013 Apr;14(4):242-7.
38. Angleman SB, Santoni G, Pilotto A et al. Multidimensional Prognostic Index in Association with Future Mortality and Number of Hospital Days in a Population-Based Sample of Older Adults: Results of the EU Funded MPI_AGE Project. PloS one 2015;10(7):e0133789.
39. Hermann DM, Kribben A, Bruck H et al. Cognitive impairment in chronic kidney disease: clinical findings, risk factors and consequences for patient care. Journal of neural transmission (Vienna, Austria: 1996) 2014 Jun;121(6):627-32
40. Banerjee G, Karia S, Varley J et al. Cognitive impairment in elderly renal inpatients: an underidentified phenomenon. Nephron. Clinical practice 2014;126(1):19-23.
41. Murray AM, Knopman DS Cognitive impairment in CKD: no longer an occult burden. American journal of kidney diseases : the official journal of the National Kidney Foundation 2010 Oct;56(4):615-8.
42. Sehgal AR, Grey SF, DeOreo PB et al. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation 1997 Jul;30(1):41-9.
43. Zammit AR, Katz MJ, Lai JY et al. Association between renal function and cognitive ability domains in the Einstein aging study: a cross-sectional analysis. The journals of gerontology. Series A, Biological sciences and medical sciences 2015 Jun;70(6):764- 70.
44. Lacson E Jr, Bruce L, Li NC et al. Depressive affect and hospitalization risk in incident hemodialysis patients. Clinical journal of the American Society of Nephrology: CJASN 2014 Oct 7;9(10):1713-9.
45. Ibrahim N, Teo SS, Che Din N et al. The Role of Personality and Social Support in Health-Related Quality of Life in Chronic Kidney Disease Patients. PloS one 2015;10(7):e0129015.
46. Murea M, Hsu FC, Cox AJ et al. Structural and functional assessment of the brain in European Americans with mild-tomoderate kidney disease: Diabetes Heart Study-MIND. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association 2015 Aug;30(8):1322-9.
47. Tiffin-Richards FE, Costa AS, Holschbach B et al. The Montreal Cognitive Assessment (MoCA) – a sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients. PloS one 2014;9(10):e106700.
48. Feng L, Yap KB, Ng TP et al. Depressive symptoms in older adults with chronic kidney disease: mortality, quality of life outcomes, and correlates. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2013 Jun;21(6):570-9.
49. Denecke C, Biebl M, Pratschke J et al. Optimizing clinical utilization and allocation of older kidneys. Current opinion in organ transplantation 2015 Aug;20(4):431-7.
50. Bozkurt B, Kılıc M Marginal Donors in Renal Transplantation. Transplantation proceedings 2015
51. McAdams-DeMarco MA, James N, Salter ML et al. Trends in kidney transplant outcomes in older adults. Journal of the American Geriatrics Society 2014 Dec;62(12):2235-42.
52. Bahde R, Vowinkel T, Unser J et al. Prognostic factors for kidney allograft survival in the Eurotransplant Senior Program. Annals of transplantation 2014 May 1;19:201.
52. Maggiore U, Cravedi P The marginal kidney donor. Curren opinion in organ transplantation 2014
53. Gandolfini I, Buzio C, Zanelli P et al. The Kidney Donor Profile Index (KDPI) of marginal donors allocated by standardized pretransplant donor biopsy assessment: distribution and associatio with graft outcomes. American journal of transplantation : official journal of the American Society of ransplantation
and the American Society of Transplant Surgeons 2014 Nov;14(11):2515-25.